Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination May 9, 2023 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Foreign Bonds Dominate: Top Performers in Last Week's Mixed Trading Back: All Posts Next:Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601